3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
SmartFinancial reported third-quarter 2026 net income of $18.6 million, or $1.10 per diluted share, up from $13.7 million, or $0.81 per share, a year earlier and $16.3 million, or $0.96 per share, in the prior quarter. Loan and lease growth of $174 million and core deposit growth of $163 million supported the results, while a lower net interest margin and higher noninterest expense partly offset those gains.
Net income of $18.6 million and diluted EPS of $1.10, compared with $16.3 million and $0.96 in Q2 2026 and $13.7 million and $0.81 in Q3 2025.
Tax equivalent net interest margin of 3.45%, down from 3.52% in the prior quarter, primarily due to higher funding costs.
Noninterest expense rose $2.4 million to $36.4 million, and income tax expense included a $2.6 million benefit from the purchase of transferable energy tax credits.
Net organic loan and lease growth of $174 million and core deposit growth of $163 million in the quarter.
Wintrust Financial Corporation reported record net income of $239.1 million, or $3.37 per diluted share, for the third quarter of 2026, up from $233.7 million, or $3.30 per diluted share, in the second quarter and $216.3 million, or $2.78 per diluted share, a year earlier. For the first nine months of 2026, net income rose 17% to $700.1 million, or $9.89 per diluted share. Net charge-offs rose to $21.0 million from $13.4 million in the prior quarter, and the net interest margin eased to 3.49%.
Net interest income rose to $621.6 million from $597.4 million in the second quarter of 2026.
Net interest margin was 3.49%, down one basis point from 3.50% in the second quarter of 2026.
Net charge-offs were $21.0 million, or 15 basis points of average total loans, up from $13.4 million, or 10 basis points.
Total deposits rose $1.3 billion to $62.4 billion, and total loans rose $1.1 billion to $56.8 billion as of September 30, 2026.
RBB Bancorp reported third-quarter 2026 net income of $12.6 million, or $0.74 per diluted share, up from $10.1 million, or $0.59, in the second quarter. The company also declared a quarterly cash dividend of $0.16 per share, payable November 12, 2026. The results include a $2.7 million gain on the sale of a Brooklyn office building, which contributed to higher noninterest income.
Net income was $12.6 million, or $0.74 per diluted share, versus $10.1 million, or $0.59, in the prior quarter
Net interest margin rose to 3.16% from 3.06%, and nonperforming assets fell to $38.7 million from $43.6 million
Quarterly cash dividend of $0.16 per common share, payable November 12, 2026, to holders of record on October 30, 2026
Results included a $2.7 million gain on the sale of an office building in Brooklyn, New York
First United Corporation reported third-quarter 2026 GAAP net income of $7.2 million, or $1.11 per diluted share, up from $6.9 million, or $1.07 per diluted share, in the third quarter of 2025. For the first nine months of 2026, net income was $19.5 million, or $3.01 per diluted share, compared with $18.7 million, or $2.88 per diluted share, a year earlier. The results show year-over-year gains in profit and earnings per share, while provision expense for credit losses rose.
Q3 2026 net income was $7.2 million, or $1.11 per diluted share, versus $6.9 million, or $1.07, in Q3 2025, and $5.7 million, or $0.88, in Q2 2026.
Nine-month 2026 net income was $19.5 million, or $3.01 per diluted share, versus $18.7 million, or $2.88, in the same period of 2025.
Provision for credit losses was $1.9 million in Q3 2026, compared with $0.5 million in Q3 2025.
The board declared a cash dividend of $0.28 per share in Q3 2026, up from $0.26 per share in Q3 2025.
On October 16, 2026, Medallion Financial agreed to buy $15.0 million in liquidation amount of trust preferred securities from BIMIZCI Fund LLC for $11.049 million, plus accrued distributions, or 73.66% of face value. The agreement also settles matters with BIMIZCI and ZimCal Asset Management, including a five-year standstill and a requirement that the investors dispose of their Medallion securities by December 31, 2026. The company expects to record a gain in the fourth quarter of 2026 and says the transaction is expected to be immediately accretive to common shareholders.
Purchase price is $11.049 million for $15.0 million liquidation amount, plus accrued distributions, the company said the deal is 73.66% of face value
Investor Parties agreed to standstill restrictions through October 16, 2031
Investor Parties agreed to sell all Medallion securities, including common stock, by December 31, 2026
Company expects a gain in the fourth quarter of 2026 equal to the difference between the $15.0 million carrying value and the cost; closing is expected within thirty days, subject to customary conditions
FrontView Operating Partnership, the operating partnership of FrontView REIT, entered Amendment No. 5 to its Credit Agreement on October 15, 2026, extending the maturity of its revolving credit facility and term loans to October 3, 2028. The amendment also lowers certain interest rate margins and replaces the revolver's usage-based commitment fee with a facility fee, which shareholders may see as lower borrowing costs and a longer repayment runway.
Amendment No. 5 dated October 15, 2026, extends the revolving credit facility and term loans to October 3, 2028.
Revolver margins before an investment-grade rating range from 1.00% to 1.65%, down from the prior terms, which the filing does not state.
Revolver usage-based commitment fee replaced with a facility fee of 0.15% to 0.30%, based on leverage ratio, before an investment-grade rating.
Full terms will be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026.
CoastalSouth Bancshares reported third-quarter 2026 net income of $8.8 million, or $0.71 per diluted share, up from $0.59 in the second quarter and $0.54 a year earlier. The board also declared a quarterly dividend of $0.06 per share, payable November 24, 2026, to holders of record on November 10, 2026. Book value per share fell to $22.32 as unrealized securities losses increased accumulated other comprehensive loss by $8.3 million.
Q3 2026 net income of $8.8 million, or $0.71 per diluted share, versus $7.3 million, or $0.59, in Q2 2026 and $6.7 million, or $0.54, in Q3 2025
Nine-month 2026 net income of $22.4 million, or $1.81 per diluted share, versus $17.8 million, or $1.58, a year earlier
Quarterly dividend of $0.06 per share declared October 19, 2026; record date November 10, 2026; payment date November 24, 2026
Book value per share was $22.32 at September 30, 2026, down from $22.47 at June 30, 2026; net interest margin was 3.70%
Metropolitan Bank Holding Corp. declared a quarterly cash dividend of $0.40 per share on October 19, 2026, up $0.05 from the prior $0.35 per share dividend. The increased dividend is payable November 10, 2026 to holders of record at the close of business on October 30, 2026, which gives shareholders a higher cash payment for each share they hold on the record date.
Quarterly cash dividend of $0.40 per share, up $0.05 from $0.35 per share
Record date is the close of business on October 30, 2026
Dividend is payable November 10, 2026
Announced in a press release dated October 19, 2026 (Exhibit 99.1)
West Coast Community Bancorp's Board of Directors declared a regular quarterly cash dividend of $0.29 per share on October 19, 2026. The filing says this is an increase of $0.04 per share over the previous quarterly dividend. The dividend is payable on or about November 6, 2026, to shareholders of record as of November 2, 2026.
Quarterly cash dividend of $0.29 per share, declared October 19, 2026
Dividend is $0.04 per share higher than the previous quarterly dividend
Record date is November 2, 2026; payment is on or about November 6, 2026
Western Alliance Bancorporation reported third quarter 2026 results for the quarter ended September 30, 2026, in a press release dated October 19, 2026, furnished under Item 2.02. Net income rose 6.4% year over year to $277.2 million and diluted earnings per share rose 7.5% to $2.45, while net revenue rose 8.1% to $1.0 billion, so the headline earnings measures improved. Non-interest expense grew 9.3% year over year, and the company repurchased $92.1 million of shares during the quarter.
Net income of $277.2 million and diluted EPS of $2.45, up 6.4% and 7.5% from the third quarter 2025
Net revenue of $1.0 billion, up 8.1% from $938.2 million a year earlier
Nonaccrual loans declined $77 million during the quarter to $485 million
Repurchased $92.1 million of shares; the company will hold its earnings call on October 20, 2026 at 12:00 p.m. ET
Washington Trust Bancorp reported unaudited third quarter 2026 net income of $19.4 million, or $1.01 per diluted share, up from $15.98 million and $0.83 per diluted share in the second quarter. Results were driven by higher net interest income, a net interest margin of 2.84%, and improved asset quality after a commercial real estate office loan was resolved. Shareholders also received a 56-cent quarterly dividend.
Net income was $19.4 million for Q3 2026, up 21% from Q2 2026 and up $8.5 million from Q3 2025.
Diluted earnings per share were $1.01, compared with $0.83 in Q2 2026 and $0.56 in Q3 2025.
Net interest margin rose to 2.84%, up 11 basis points from the prior quarter, and nonaccrual loans fell to $24.5 million from $39.8 million.
Book value per share declined to $27.82 from $29.02, as accumulated other comprehensive loss increased to $109.8 million.
SpyGlass Pharma announced interim 4-year results from its first-in-human trial of the Bimatoprost Drug Pad-IOL System, a cataract-surgery implant designed to lower eye pressure for glaucoma or ocular hypertension patients. The company reported a 37% mean reduction in intraocular pressure and no product-related adverse events among 21 evaluable patients, though the study is small and the product remains in clinical development with no approval yet.
Mean intraocular pressure fell 37%, from 25.1 to 15.9 mmHg, across all three dose groups at 4 years
86% of evaluable patients (18 of 21) remained off all topical IOP-lowering drops
No product-related adverse events were reported; the trial began with 23 patients, and 21 were evaluable at 48 months
Company plans to work with the FDA on a 505(b)(2) New Drug Application; long-term follow-up continues through 2029
Crown Holdings reported third quarter 2026 results for the period ended September 30, 2026. Net sales rose to $3,711 million from $3,202 million, and adjusted diluted earnings per share increased 7% to $2.39, while segment income slipped to $484 million from $490 million. The company also gave full-year 2026 adjusted diluted EPS guidance of $8.35 to $8.45 and adjusted free cash flow of at least $950 million.
Q3 2026 reported diluted EPS was $2.08 versus $1.85 in 2025; net income attributable to Crown Holdings was $225 million versus $214 million.
Global beverage can volumes increased 6% in the quarter, and the company repurchased $81 million of its common stock.
Fourth quarter 2026 adjusted diluted EPS is expected in the range of $1.63 to $1.73.
Results will be discussed on a conference call on October 20, 2026 at 9:00 a.m. EDT.
Zions Bancorporation reported third-quarter 2026 net earnings of $262 million, or $1.78 per diluted share, up from $221 million and $1.48 a year earlier. The increase was driven mainly by a lower provision for credit losses, which was an $8 million benefit versus a $49 million expense last year, and net loan charge-offs fell to $3 million from $56 million.
Net earnings $262 million and diluted EPS $1.78, versus $221 million and $1.48 in third quarter 2025
Net interest income $684 million, up 2%; net interest margin 3.23%, down from 3.28%
Pre-provision net revenue $340 million, down 1%; net charge-offs $3 million versus $56 million
Compared with second quarter 2026 net earnings of $452 million and EPS of $3.05, which included gains tied to Visa Class B-1 share sales
Scienture Holdings reported preliminary, unaudited revenue of about $1.22 million for the quarter ended September 30, 2026, up 256% from about $344,000 in the second quarter, driven by the August 2026 REZENOPY launch and continued Arbli sales growth. The company also regained compliance with Nasdaq's $1.00 minimum bid price requirement, and Nasdaq closed the matter, so its common stock will remain listed. The filing does not report profit or earnings per share for the quarter.
Preliminary unaudited Q3 2026 revenue of about $1.22 million, versus about $344,000 in Q2 2026 (up 256%).
Arbli wholesale unit sales rose 74% sequentially; REZENOPY launched in August 2026 with initial wholesale shipments.
On October 19, 2026, Nasdaq confirmed the stock closed at or above $1.00 for ten consecutive trading days, and the matter is closed.
ServisFirst Bancshares reported third-quarter 2026 net income of $87.3 million, or $0.80 per diluted share, up from $65.6 million, or $0.60, a year earlier, and up slightly from $0.78 in the second quarter. The company also said it announced its first stock repurchase program after quarter-end, authorizing up to two million shares through December 31, 2027. Shareholders get a higher reported profit per share, along with a buyback authorization that the company has not yet begun to use according to the filing.
Diluted EPS of $0.80 versus $0.60 in Q3 2025, a 33% increase; net interest margin held at 3.63%, unchanged from Q2 2026
Loans grew $1.43 billion, or 10.7%, year over year to $14.74 billion at September 30, 2026
Noninterest expense rose 8.8% year over year to $52.2 million, while the efficiency ratio improved to 30.20% from 35.22%
Two-for-one stock split completed in the quarter; repurchase program authorizes up to two million shares through December 31, 2027
Peoples Bancorp of North Carolina reported third quarter 2026 net earnings of $5.7 million, or $1.05 per diluted share, up from $3.7 million, or $0.67 per diluted share, a year earlier. The gain was driven mainly by higher net interest income and lower non-interest expense, with net interest margin rising to 3.85% from 3.58%.
Q3 2026 net earnings $5.7 million, or $1.05 per diluted share, versus $3.7 million, or $0.67 per diluted share, in Q3 2025
Net interest income rose to $16.7 million from $15.1 million; non-interest income fell to $6.7 million from $7.1 million
Non-interest expense fell to $15.8 million from $16.9 million; nine-month net earnings were $15.4 million, or $2.81 per diluted share
Veradermics said its Phase 3 Study '304' of VDPHL01, an oral extended-release minoxidil tablet, met all primary and secondary endpoints with high statistical significance in 536 men with mild-to-moderate pattern hair loss. The company reported no treatment-related serious adverse events and no cardiac adverse events of special interest, and it said the results add to positive data from Study '302' for a potential first FDA-approved oral non-hormonal treatment for men, though approval has not been sought or granted.
At Month 6, hair count rose 28.6 hairs/cm² (once daily) and 36.4 hairs/cm² (twice daily) versus 6.6 hairs/cm² for placebo, each with p<0.0001.
55.7% (once daily) and 68.7% (twice daily) of patients reported 'improved' or 'much improved' hair coverage versus 15.0% on placebo.
Hypertrichosis was the only adverse event above 5% with a difference from placebo: 2.2% (once daily) and 9.0% (twice daily) versus 0% on placebo.
Veradermics plans to report Part B of Study '302' later in 2026.
Silence Therapeutics agreed on October 18, 2026 to be acquired by Merck KGaA, Darmstadt, Germany in an all-cash deal valued at about $1.3 billion in equity value. Shareholders and ADS holders would receive $20.00 in cash per American Depositary Share, a 130% premium to the October 16, 2026 closing ADS price, and the transaction was unanimously approved by the Silence board.
Consideration of $20.00 in cash per ADS, with each ADS representing three ordinary shares ($6.6667 per share)
Equity value of approximately $1.3 billion and enterprise value of $1.1 billion; 82% premium to the 30-day volume-weighted average price of $10.99
Expected close in the first quarter of 2027, subject to shareholder approval, High Court sanction and regulatory approvals; End Date of April 30, 2027
Silence must pay Merck KGaA a $13 million termination fee in certain circumstances; securityholders with about 14% of voting power signed voting and support agreements
Silgan Holdings said it will combine its Metal Containers and Food and Beverage Flat Cap Closures businesses with Trivium Packaging in a partnership with funds affiliated with American Industrial Partners (AIP), with the partnership acquiring Trivium in an all-cash deal at a $3.4 billion enterprise value. Silgan expects about $2.3 billion of cash proceeds and a 60% stake in the new partnership, and it expects the deal to be at least 15% accretive to adjusted EPS and free cash flow, including $225 million of expected synergies. The deal is expected to close in mid-2027, subject to regulatory approvals and other conditions, and Silgan confirmed its third-quarter and full-year 2026 adjusted EPS outlook.
Silgan MCC will combine Silgan's Metal Containers and Flat Cap Closures businesses with Trivium at a $3.4 billion enterprise value for Trivium, or 7.1x LTM Adjusted EBITDA
Silgan receives approximately $2.3 billion of cash proceeds and retains 60% ownership; AIP holds 40% and contributes approximately $1.0 billion of cash equity
Expected synergies of $225 million by year three, with about $75 million in year one and $150 million in year two; Silgan expects at least 15% adjusted EPS accretion
Expected close in mid-2027; Silgan MCC net leverage estimated at about 4.0x pro forma
EquipmentShare raised its full-year 2026 financial guidance for a second time, citing strong customer demand, disciplined execution and rising productivity across its rental network. The higher outlook covers total revenue and Adjusted Core EBITDA, and the company says the increase reflects growth in its rental operations, though it has not yet reported actual results for the quarter ended September 30, 2026.
Total revenue guidance is now $5,808 million to $6,045 million, up from $5,254 million to $5,682 million under prior guidance dated July 9, 2026.
Adjusted Core EBITDA guidance is now $2,136 million to $2,224 million, up from $1,946 million to $2,058 million.
The midpoint full-year growth outlook for the Equipment Rental and Services Operations segment revenue increased to 43% from 33%.
Actual results for the quarter ended September 30, 2026 will be provided at the third quarter earnings call.
Disc Medicine reported topline results from the pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP), saying the trial met all primary and secondary endpoints. The company plans to resubmit a New Drug Application to the FDA by the end of 2026, with an FDA decision anticipated by mid-2027, so the results bear directly on the timing of a possible approval for its lead program.
Both co-primary endpoints were statistically significant: whole-blood PPIX fell 41.4% vs. placebo (p<0.0001), and time in light without pain rose 12.2 hours vs. placebo (p=0.0010)
Phototoxic reactions fell in incidence (p<0.0001 vs. placebo), and dizziness was the most common adverse event in the bitopertin group at 50%
The trial enrolled 183 patients, and the company plans an NDA resubmission by end of 2026 with an FDA decision anticipated by mid-2027
Cleveland-Cliffs reported third-quarter 2026 revenues of $5.6 billion, up from $5.2 billion in the second quarter, and GAAP net income of $165 million, or $0.26 per diluted share, compared with a second-quarter net loss of $134 million. The company also said it expects fourth-quarter adjusted EBITDA of about $715 million and 2027 adjusted EBITDA above $4 billion, and it will indefinitely idle its Stelco galvanizing lines.
Q3 adjusted EBITDA was $612 million, up from $286 million in Q2 2026 and above the $575 million guidance given three months earlier
Fourth-quarter 2026 adjusted EBITDA is expected to be approximately $715 million
2027 adjusted EBITDA is expected to exceed $4 billion, based on new contracts and prevailing index price forecasts
Liquidity was $3.2 billion as of September 30, 2026; Stelco's galvanizing lines are idled indefinitely
Jefferies Financial Group posted an investor presentation on its website for its October 19, 2026 investor meeting, furnished as Exhibit 99.1 to a Form 8-K. The deck reports trailing-twelve-month results through the third quarter of 2026, including $8.5 billion in net revenues and $0.9 billion in net earnings to all shareholders, and it reviews its pending acquisition of Hildene/SILAC and a planned Japan Equities joint venture with SMBC.
Presentation posted October 19, 2026 for the company's October 19, 2026 Investor Meeting; filed as Exhibit 99.1
LTM Q3'26 net revenues of $8.5 billion, up 119% since 2019; net earnings to all shareholders of $0.9 billion, up 123% since 2019
Pending acquisition: Jefferies intends to acquire a 50% interest in Hildene Holding Company, which is acquiring SILAC, as disclosed in September 2025
Japan Equities joint venture with SMBC is scheduled to launch January 1, 2027
Fifth Third Bancorp reported third quarter 2026 net income available to common shareholders of $828 million, or $0.90 per diluted share, up from $763 million, or $0.83 per share, in the second quarter, but roughly flat with the $0.91 per share earned a year earlier. Excluding $0.23 per share of certain items, mainly merger-related charges tied to the Comerica acquisition, adjusted EPS was $1.13.
Net income available to common shareholders was $828 million, compared with $763 million in the prior quarter and $608 million a year earlier.
Diluted EPS was $0.90, versus $0.83 in the second quarter and $0.91 in the third quarter of 2025; adjusted EPS was $1.13.
Certain items reduced results by $211 million after tax, including $171 million of merger-related charges.
Net interest income rose 3% sequentially to $2.28 billion, while noninterest income fell 5% to $1.01 billion.
Transocean Ltd. announced contract awards for two ultra-deepwater drillships in the U.S. Gulf, with undisclosed operators, adding about $550 million in firm contract backlog. The Deepwater Proteus and Deepwater Conqueror awards are expected to begin in 2027, each directly continuing the rig's current work. The filing adds contracted future work for shareholders but includes no earnings or guidance figures.
Deepwater Proteus: ten-well contract, estimated 700-day campaign, about $325 million in backlog, starting in the first quarter of 2027
Deepwater Conqueror: five-well contract, estimated 450 days of work, about $225 million in backlog excluding mobilization fees, starting in the third quarter of 2027
Both awards are with undisclosed operators in the U.S. Gulf and follow directly on from each rig's existing program
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.